Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crizotinib and Sunitinib in Metastatic Breast Cancer
NCT02074878Phase 1Terminated
- Sponsor
- Mothaffar Rimawi
- Start
- Jun 2014
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of crizotinib and sunitinib in breast cancer (3 cohorts), sponsored by Mothaffar Rimawi. Primary endpoint: Maximum Tolerated Dose at 1 year. Started Jun 2014; status: terminated.
02
Drugs
crizotinibsunitinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02074878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02074878.